In-House Insights
Accelerating Oncology Discoveries with TaqMan Assays: Precision Tools for Cancer Research
TaqMan assays have become essential tools in oncology research, enabling precise gene expression analysis, tumor biomarker validation, and molecular pathway investigation. Their high sensitivity, specificity, and reproducibility support cancer discovery efforts, translational research, and precision medicine initiatives. These assays help researchers accelerate the development of targeted therapies and personalized treatment strategies.
Next-Generation ADCs: Process Development Strategies for Antibody-Oligonucleotide Conjugates
Abstract: Antibody-oligonucleotide conjugates are expanding the possibilities of targeted therapeutics beyond traditional ADC applications. However, their complexity introduces new challenges in process development, manufacturing, scale-up, and CMC strategy. This article explores key considerations for developing robust, scalable processes that can help accelerate clinical readiness while reducing development and manufacturing risks.
Advancing CAR-T Therapies: Overcoming Development and Manufacturing Challenges for Clinical Success
Abstract: CAR-T and TCR therapies are advancing personalized medicine by offering innovative treatment options for cancer, autoimmune disorders, and rare diseases. However, challenges related to manufacturing, scalability, and process consistency remain significant. This article explores key development hurdles, emerging CAR-T manufacturing solutions, process optimization strategies, and opportunities for future clinical success.
How to Accelerate IND-Enabling Toxicology Studies in Today's Drug Development Environment
A decade ago, toxicology was not usually one of the first things to cross the minds of development teams when planning timelines to an IND. Project meetings were frequently dominated by manufacturing, formulation or regulatory discussions.
.webp)
Advances in Process Liquid Outsourcing for CDMOs
Today, the biopharmaceutical industry is in the midst of a structural change, as products get more complex, regulatory requirements become more demanding and the pressure to get products to market is growing. CDMOs are emerging as significant providers of a scalable, compliant, cost-effective biologics manufacturing in a dynamic market.
